CN110168084A - 用于内源和来源DNA的单发指导RNA(ogRNA)靶向的系统和方法 - Google Patents
用于内源和来源DNA的单发指导RNA(ogRNA)靶向的系统和方法 Download PDFInfo
- Publication number
- CN110168084A CN110168084A CN201780082711.XA CN201780082711A CN110168084A CN 110168084 A CN110168084 A CN 110168084A CN 201780082711 A CN201780082711 A CN 201780082711A CN 110168084 A CN110168084 A CN 110168084A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- lys
- sequence
- leu
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430154P | 2016-12-05 | 2016-12-05 | |
| US62/430,154 | 2016-12-05 | ||
| US201762503640P | 2017-05-09 | 2017-05-09 | |
| US62/503,640 | 2017-05-09 | ||
| PCT/US2017/064720 WO2018106693A1 (en) | 2016-12-05 | 2017-12-05 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110168084A true CN110168084A (zh) | 2019-08-23 |
Family
ID=60972337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780082711.XA Pending CN110168084A (zh) | 2016-12-05 | 2017-12-05 | 用于内源和来源DNA的单发指导RNA(ogRNA)靶向的系统和方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9963719B1 (enExample) |
| EP (1) | EP3548614A1 (enExample) |
| JP (2) | JP7272952B2 (enExample) |
| KR (1) | KR102604903B1 (enExample) |
| CN (1) | CN110168084A (enExample) |
| AU (1) | AU2017373797B2 (enExample) |
| CA (1) | CA3046076A1 (enExample) |
| MX (2) | MX2019006475A (enExample) |
| WO (1) | WO2018106693A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| CN109312338B (zh) * | 2015-10-30 | 2022-09-27 | 爱迪塔斯医药公司 | 治疗单纯疱疹病毒的crispr/cas相关方法及组合物 |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3714055A1 (en) | 2017-11-21 | 2020-09-30 | CRISPR Therapeutics AG | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| WO2019118875A1 (en) * | 2017-12-15 | 2019-06-20 | Ou Li | Crispr-mediated genome editing with vectors |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| US12227547B2 (en) | 2018-09-10 | 2025-02-18 | The Regents Of The University Of California | Modulators of CAS9 polypeptides and methods of use thereof |
| US20220133768A1 (en) | 2019-02-25 | 2022-05-05 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| US20220145274A1 (en) * | 2019-03-12 | 2022-05-12 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
| US12173290B2 (en) | 2019-06-28 | 2024-12-24 | Crispr Therapeutics Ag | Materials and methods for controlling gene editing |
| WO2021053582A1 (en) * | 2019-09-18 | 2021-03-25 | Crispr Therapeutics Ag | All-in-one self inactivating crispr vectors |
| WO2021062201A1 (en) * | 2019-09-25 | 2021-04-01 | Spotlight Therapeutics | Compositions and methods for nucleoprotein targeting and expression |
| EP4157903A2 (en) * | 2020-05-29 | 2023-04-05 | Regents of the University of Minnesota | Copolymers for intracellular therapeutic nucleic acid payload delivery |
| EP4255502A4 (en) * | 2020-12-03 | 2025-07-16 | Scribe Therapeutics Inc | COMPOSITIONS AND METHODS FOR TARGETING BCL11A |
| WO2022221741A1 (en) | 2021-04-16 | 2022-10-20 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| WO2025179057A1 (en) * | 2024-02-21 | 2025-08-28 | The Regents Of The University Of California | In vivo modification of cell genomes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015070083A1 (en) * | 2013-11-07 | 2015-05-14 | Editas Medicine,Inc. | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
| WO2015089351A1 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
| WO2016176404A1 (en) * | 2015-04-30 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Methods and kits for cloning-free genome editing |
| WO2016183438A1 (en) * | 2015-05-14 | 2016-11-17 | Massachusetts Institute Of Technology | Self-targeting genome editing system |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| AU2016226077B2 (en) * | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| PL3298134T3 (pl) | 2015-05-16 | 2023-09-18 | Genzyme Corporation | Edycja genów mutacji głęboko intronowych |
| WO2017136335A1 (en) * | 2016-02-01 | 2017-08-10 | The Regents Of The University Of California | Self-inactivating endonuclease-encoding nucleic acids and methods of using the same |
| WO2017173004A1 (en) * | 2016-03-30 | 2017-10-05 | Mikuni Takayasu | A method for in vivo precise genome editing |
-
2017
- 2017-12-05 US US15/832,567 patent/US9963719B1/en active Active
- 2017-12-05 EP EP17829373.4A patent/EP3548614A1/en active Pending
- 2017-12-05 AU AU2017373797A patent/AU2017373797B2/en active Active
- 2017-12-05 WO PCT/US2017/064720 patent/WO2018106693A1/en not_active Ceased
- 2017-12-05 JP JP2019530105A patent/JP7272952B2/ja active Active
- 2017-12-05 CN CN201780082711.XA patent/CN110168084A/zh active Pending
- 2017-12-05 MX MX2019006475A patent/MX2019006475A/es unknown
- 2017-12-05 CA CA3046076A patent/CA3046076A1/en active Pending
- 2017-12-05 KR KR1020197019386A patent/KR102604903B1/ko active Active
-
2018
- 2018-03-23 US US15/934,750 patent/US10006054B1/en active Active
- 2018-05-15 US US15/980,450 patent/US10494649B2/en active Active
-
2019
- 2019-06-03 MX MX2024002327A patent/MX2024002327A/es unknown
- 2019-10-29 US US16/666,982 patent/US11028411B2/en active Active
-
2021
- 2021-05-27 US US17/332,764 patent/US11692205B2/en active Active
-
2022
- 2022-12-26 JP JP2022208855A patent/JP2023052089A/ja not_active Withdrawn
-
2023
- 2023-05-12 US US18/316,880 patent/US12264331B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015070083A1 (en) * | 2013-11-07 | 2015-05-14 | Editas Medicine,Inc. | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
| WO2015089351A1 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
| WO2016176404A1 (en) * | 2015-04-30 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Methods and kits for cloning-free genome editing |
| WO2016183438A1 (en) * | 2015-05-14 | 2016-11-17 | Massachusetts Institute Of Technology | Self-targeting genome editing system |
Non-Patent Citations (5)
| Title |
|---|
| BENJAMIN E. EPSTEIN 等: "Engineering a Self-Inactivating CRISPR System for AAV Vectors", 《MOLECULAR THERAPY》 * |
| KAIWEN IVY LIU等: "A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing", 《NATURE CHEMICAL BIOLOGY》 * |
| P. SINGHAL 等: "Self-Inactivating Cas9: A Method for Reducing Exposure While Maintaining Efficacy in Virally-Delivered Cas9 Applications", 《EDITAS MEDICINE: PUBLICATIONS&PRESENTATIONS》 * |
| RICHARD MOORE 等: "CRISPR- based controllable gene delivery in human self-cleaving mechanism for cells", 《NUCLEIC ACIDS RESEARCH》 * |
| 肖婧 等: "CRISPR-Cas9系统在真核细胞领域内的研究进展", 《标记免疫分析与临床》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10006054B1 (en) | 2018-06-26 |
| US20230416787A1 (en) | 2023-12-28 |
| EP3548614A1 (en) | 2019-10-09 |
| US9963719B1 (en) | 2018-05-08 |
| MX2019006475A (es) | 2019-09-26 |
| US11692205B2 (en) | 2023-07-04 |
| AU2017373797B2 (en) | 2024-08-29 |
| KR102604903B1 (ko) | 2023-11-21 |
| KR20190088555A (ko) | 2019-07-26 |
| US11028411B2 (en) | 2021-06-08 |
| CA3046076A1 (en) | 2018-06-14 |
| JP7272952B2 (ja) | 2023-05-12 |
| US10494649B2 (en) | 2019-12-03 |
| US20180251792A1 (en) | 2018-09-06 |
| US20220017927A1 (en) | 2022-01-20 |
| JP2019536462A (ja) | 2019-12-19 |
| MX2024002327A (es) | 2024-03-07 |
| US20180201956A1 (en) | 2018-07-19 |
| JP2023052089A (ja) | 2023-04-11 |
| US12264331B2 (en) | 2025-04-01 |
| US20200056208A1 (en) | 2020-02-20 |
| WO2018106693A1 (en) | 2018-06-14 |
| AU2017373797A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102604903B1 (ko) | 내인성 및 공급원 DNA의 원-샷 가이드 RNA(ogRNA) 표적화를 위한 시스템 및 방법 | |
| JP7610559B2 (ja) | 合成ガイド分子、それに関連する組成物および方法 | |
| KR102907245B1 (ko) | 혈색소병증 치료를 위한 시스템 및 방법 | |
| US12359223B2 (en) | Systems and methods for modulating chromosomal rearrangements | |
| US20200299661A1 (en) | Cpf1-related methods and compositions for gene editing | |
| US20240167059A1 (en) | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites | |
| US12214055B2 (en) | Systems and methods for treating hyper-igm syndrome | |
| CN121399263A (zh) | 用于增加同源定向修复的方法和组合物 | |
| KR20260019520A (ko) | Fl1-1 발현을 표적화하는 crispr 관련 방법 및 조성물 | |
| KR20260018069A (ko) | Ptpn2 발현을 표적화하는 crispr 관련 방법 및 조성물 | |
| NZ795268A (en) | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190823 |
|
| WD01 | Invention patent application deemed withdrawn after publication |